Hutchmed (China) Limited Total Voting Rights (0741V)
November 30 2023 - 3:30AM
UK Regulatory
TIDMHCM
RNS Number : 0741V
Hutchmed (China) Limited
30 November 2023
Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ -- Thursday,
November 30, 2023: HUTCHMED (China) Limited ("HUTCHMED")
(Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at
November 30, 2023, the issued share capital of HUTCHMED consisted
of 871,172,770 ordinary shares of US$0.10 each, with each share
carrying one right to vote and with no shares held in treasury.
The above figure of 871,172,770 may be used by shareholders as
the denominator for the calculations by which they could determine
if they are required to notify their interest in, or a change to
their interest in, HUTCHMED under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.
For illustrative purposes only, the 871,172,770 ordinary shares
would be equivalent to 871,172,770 depositary interests (each
equating to one ordinary share) which are traded on AIM or, if the
depositary interests were converted in their entirety, equivalent
to 174,234,554 American depositary shares (each equating to five
ordinary shares) which are traded on Nasdaq.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery and global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. It has approximately 5,000 personnel across
all its companies, at the center of which is a team of about 1,800
in oncology/immunology. Since inception it has focused on bringing
cancer drug candidates from in-house discovery to patients around
the world, with its first three medicines marketed in China, the
first of which is also marketed in the U.S.. For more information,
please visit: www.hutch-med.com or follow us on LinkedIn.
Contacts
Investor Enquiries +852 2121 8200 / +1 973 306 4490 / ir@hutch-med.com
Media Enquiries
Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
545 055 (Mobile) / HUTCHMED@fticonsulting.com
Zhou Yi, Brunswick +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure
Gordon +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRKZMZMLLDGFZG
(END) Dow Jones Newswires
November 30, 2023 03:30 ET (08:30 GMT)
HUTCHMED China (AQSE:HCM.GB)
Historical Stock Chart
From Jul 2024 to Aug 2024
HUTCHMED China (AQSE:HCM.GB)
Historical Stock Chart
From Aug 2023 to Aug 2024